Teriflunomide Viatris (previously Teriflunomide Mylan)

[ad_1]

Overview

Teriflunomide Viatris is a medicine used to treat patients from the age of 10 years with multiple sclerosis (MS), a disease in which inflammation attacks the protective covering (sheath) around nerves and damages the nerves themselves.

Teriflunomide Viatris is used in the type of MS known as relapsing-remitting MS, when the patient has flare-ups of symptoms (relapses) followed by periods of recovery (remissions).

Teriflunomide Viatris contains the active substance teriflunomide and is a ‘generic medicine’. This means that Teriflunomide Viatris contains the same active substance and works in the same way as a ‘reference medicine’ already authorised in the EU called Aubagio. For more information on generic medicines, see the question-and-answer document here.

Teriflunomide Viatris can only be obtained with a prescription and treatment should be started and supervised by a doctor who has experience in the management of MS.

Teriflunomide Viatris is available as tablets to be taken once a day.

For more information about using Teriflunomide Viatris, see the package leaflet or contact your doctor or pharmacist.

In multiple sclerosis, the immune system (the body’s natural defences) attacks the protective sheath around the nerves and the nerves themselves in the brain and spinal cord. The active substance in Teriflunomide Viatris, teriflunomide, blocks an enzyme called dihydroorotate dehydrogenase which is necessary for cells to multiply. The exact way teriflunomide works in MS is not known but it is thought to reduce the number of T lymphocytes which form part of the immune system and are involved in the inflammation process. With fewer T lymphocytes, there is less inflammation, helping to control the symptoms of MS.

Studies on the benefits and risks of the active substance in the authorised use have already been carried out with the reference medicine, Aubagio, and do not need to be repeated for Teriflunomide Viatris.

As for every medicine, the company provided studies on the quality of Teriflunomide Viatris. The company also carried out a study that showed that it is ‘bioequivalent’ to the reference medicine. Two medicines are bioequivalent when they produce the same levels of the active substance in the body and are therefore expected to have the same effect.

Because Teriflunomide Viatris is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine’s.

The European Medicines Agency concluded that, in accordance with EU requirements, Teriflunomide Viatris has been shown to have comparable quality and to be bioequivalent to Aubagio. Therefore, the Agency’s view was that, as for Aubagio, the benefits of Teriflunomide Viatris outweigh the identified risks and it can be authorised for use in the EU.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Teriflunomide Viatris have also been included in the summary of product characteristics and the package leaflet. Any additional measures in place for Aubagio, such as educational material for healthcare professionals and a patient card with key safety information, also apply to Teriflunomide Viatris where appropriate.

As for all medicines, data on the use of Teriflunomide Viatris are continuously monitored. Suspected side effects reported with Teriflunomide Viatris are carefully evaluated and any necessary action taken to protect patients.

Teriflunomide Mylan received a marketing authorisation valid throughout the EU on 9 November 2022.

The name of the medicine was changed to Teriflunomide Viatris on 15 October 2024.

English (EN)
(146.56 KB – PDF)

First published: 22/11/2022Last updated: 28/01/2025

View

English (EN)
(146.41 KB – PDF)

First published: 22/11/2022

View

Product information

English (EN)
(296 KB – PDF)

First published: 22/11/2022Last updated: 08/01/2025

View

Latest procedure affecting product information:
T/0010

19/12/2024

This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

Product information documents contain:

summary of product characteristics (annex I);
manufacturing authorisation holder responsible for batch release (annex IIA);
conditions of the marketing authorisation (annex IIB);
labelling (annex IIIA);
package leaflet (annex IIIB).

English (EN)
(12.21 KB – PDF)

First published: 22/11/2022Last updated: 17/10/2024

View

Product details

Name of medicine: Teriflunomide Viatris (previously Teriflunomide Mylan)
Active substance: Teriflunomide
International non-proprietary name (INN) or common name: teriflunomide
Therapeutic area (MeSH): Multiple Sclerosis, Relapsing-Remitting
Anatomical therapeutic chemical (ATC) code: L04AA31

Pharmacotherapeutic group

Immunosuppressants

Therapeutic indication

Teriflunomide Mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (MS) (please refer to section 5.1 of the SmPC for important information on the population for which efficacy has been established).

More information on Teriflunomide Mylan

English (EN)
(66.45 KB – PDF)

First published: 09/07/2007Last updated: 07/12/2012

View

[ad_2]

Source link

Subscribe now

To access premium content

The Battle of The Metaverse is Just Getting Started

Vulcan Scholarships, Town Star Nodes, The Sandbox Alpha Event

Smart Gamers Talk About NFTs and Play to Earn

CoronaVirus: Calling Gamers to Help Combat It

BLAST Premier 2022 – Betting Tips and Schedule

Zendodo Party Review: Where NFTs Meets DeFi on WAX

Genesis Worlds Metaverse Review – A 100 Years Project

Non-Fungible: A Play-To-Earn Substances Selling Game

Is Overwatch League Getting Outsourced A Good Thing?

Dreamverse NFT Festival: Interview With Twobadour

Inside Axie Infinity With Jihoz – Growth Lead

Alien Worlds Interview With Co-Founder Saro Mckenna

Talking Hash Rush With CMO Alexander Benitez & CM

Gala Games Town Star & Mirandus With Jason Brink